---
title: Osteogenesis Imperfecta grouping deep research
keywords:
- grouping
- osteogenesis-imperfecta
- skeletal-dysplasia
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-06-13T18:06:06.727611'
end_time: '2026-06-13T18:22:47.201852'
duration_seconds: 1000.47
provider_config:
  timeout: null
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
    max_tokens: 12000
    max_embedded_images: 8
citation_count: 44
artifact_count: 2
artifact_sources:
  edison_answer_artifacts: 2
artifacts:
- filename: artifact-00.md
  path: Osteogenesis_Imperfecta-deep-research-falcon_artifacts/artifact-00.md
  media_type: text/markdown
  source: edison_answer_artifacts
  data_storage_id: null
  description: Edison artifact artifact-00
- filename: artifact-01.md
  path: Osteogenesis_Imperfecta-deep-research-falcon_artifacts/artifact-01.md
  media_type: text/markdown
  source: edison_answer_artifacts
  data_storage_id: null
  description: Edison artifact artifact-01
---

## Question

Prepare a focused, citation-rich deep research report for a dismech disease grouping called 'Osteogenesis Imperfecta'. The grouping should be an explicit curated union of Disease entries, not merely a MONDO hierarchy clone. Current likely candidate members in the knowledge base include Osteogenesis Imperfecta Type I, Type II, Type III, Type IV, Type V, and Type VII. Research objectives: 1. define shared OI pathophysiology across type I collagen quantitative defects, dominant-negative collagen structural defects, collagen folding/post-translational modification, osteoblast dysfunction, low bone mineral density, abnormal bone matrix, skeletal fragility, and multisystem connective-tissue manifestations; 2. distinguish major subtype mechanisms and genes including COL1A1/COL1A2, IFITM5, CRTAP, and high-value missing OI genes/types such as SERPINF1, P3H1/LEPRE1, PPIB, FKBP10, SERPINH1, BMP1, WNT1, CREB3L1, SP7, TMEM38B, PLOD2, MESD, MBTPS2, KDELR2, and CCDC134 where relevant; 3. recommend a defensible grouping boundary and explicitly flag disorders to exclude such as atelosteogenesis, achondrogenesis, hypophosphatasia, Ehlers-Danlos/OI overlap unless curated as OI, osteoporosis, and other skeletal dysplasias; 4. list differentiating mechanisms for existing and high-value missing subtype entries; 5. identify appropriate MONDO mapping, HPO phenotype criteria, and any dismech module-conformance criteria or module gaps for the grouping YAML; 6. provide primary literature, GeneReviews, management guidelines, bisphosphonate/orthopedic evidence, and authoritative review citations with PMID identifiers wherever possible; 7. flag knowledge gaps, nomenclature pitfalls, and model-system limitations relevant to collagen biology, bone fragility, and therapy. Do not invent citations; prefer PubMed-indexed sources and provide exact PMID identifiers for key claims.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Prepare a focused, citation-rich deep research report for a dismech disease grouping called 'Osteogenesis Imperfecta'. The grouping should be an explicit curated union of Disease entries, not merely a MONDO hierarchy clone. Current likely candidate members in the knowledge base include Osteogenesis Imperfecta Type I, Type II, Type III, Type IV, Type V, and Type VII. Research objectives: 1. define shared OI pathophysiology across type I collagen quantitative defects, dominant-negative collagen structural defects, collagen folding/post-translational modification, osteoblast dysfunction, low bone mineral density, abnormal bone matrix, skeletal fragility, and multisystem connective-tissue manifestations; 2. distinguish major subtype mechanisms and genes including COL1A1/COL1A2, IFITM5, CRTAP, and high-value missing OI genes/types such as SERPINF1, P3H1/LEPRE1, PPIB, FKBP10, SERPINH1, BMP1, WNT1, CREB3L1, SP7, TMEM38B, PLOD2, MESD, MBTPS2, KDELR2, and CCDC134 where relevant; 3. recommend a defensible grouping boundary and explicitly flag disorders to exclude such as atelosteogenesis, achondrogenesis, hypophosphatasia, Ehlers-Danlos/OI overlap unless curated as OI, osteoporosis, and other skeletal dysplasias; 4. list differentiating mechanisms for existing and high-value missing subtype entries; 5. identify appropriate MONDO mapping, HPO phenotype criteria, and any dismech module-conformance criteria or module gaps for the grouping YAML; 6. provide primary literature, GeneReviews, management guidelines, bisphosphonate/orthopedic evidence, and authoritative review citations with PMID identifiers wherever possible; 7. flag knowledge gaps, nomenclature pitfalls, and model-system limitations relevant to collagen biology, bone fragility, and therapy. Do not invent citations; prefer PubMed-indexed sources and provide exact PMID identifiers for key claims.

## Osteogenesis Imperfecta (OI) — curated disease grouping deep research report (dismech)

### 0. Executive summary
Osteogenesis imperfecta (OI) is a genetically heterogeneous heritable skeletal dysplasia characterized by intrinsic bone fragility (recurrent low‑trauma fractures), low bone mass, deformity and growth deficiency, plus multisystem connective‑tissue manifestations (e.g., dentinogenesis imperfecta, hearing loss). Contemporary expert consensus increasingly treats OI as a *collagen-related disorder* that includes classic type I collagen chain defects **and** non-collagen genes whose products modulate collagen folding, post-translational modification, processing/trafficking, mineralization, and osteoblast differentiation/signaling. (jovanovic2024updateonthe pages 2-4, yu2023pathogenicmechanismsof pages 1-2, jovanovic2024updateonthe pages 1-2)

A defensible dismech disease grouping for “Osteogenesis Imperfecta” should therefore be an explicit union of curated disease entries spanning: (i) dominant COL1A1/COL1A2 quantitative and dominant-negative structural disorders (Sillence I–IV), (ii) distinctive non-collagen OI such as IFITM5-related type V, and (iii) high-value recessive and X-linked OI subtypes affecting collagen PTM/folding, mineralization, and osteoblast signaling (e.g., CRTAP, P3H1/LEPRE1, SERPINF1, SERPINH1, FKBP10, MBTPS2, KDELR2, etc.). (sillence2024adyadicnosology pages 1-2, jovanovic2024updateonthe pages 2-4, yu2023pathogenicmechanismsof pages 1-2)

### 1. Key concepts and definitions (current understanding)

#### 1.1 Definition and shared clinical phenotype
Recent authoritative reviews define OI as a heritable bone fragility disorder with skeletal fragility and deformity, growth deficiency, and connective-tissue manifestations beyond the skeleton. (jovanovic2024updateonthe pages 2-4, yu2023pathogenicmechanismsof pages 1-2)

In large modern cohorts, the typical burden includes extremely high fracture prevalence and frequent vertebral compression fractures (VCFs). For example, in a 2024 cohort of 414 OI probands, **peripheral fractures were reported in 96.6%**, and **VCFs in 43.5%**. (lin2024genotype–phenotyperelationshipand pages 2-4, lin2024genotype–phenotyperelationshipand pages 4-5)

#### 1.2 Shared molecular pathophysiology: “collagen-related” common pathway
Across classic and rare OI, shared pathophysiology is now framed as disruption of:
- **Type I collagen quantity** (e.g., COL1A1 haploinsufficiency → less normal collagen). (hasegawa2025osteogenesisimperfectapathogenesis pages 1-2, jovanovic2024updateonthe pages 2-4)
- **Type I collagen structure** (dominant-negative collagen chain variants, often glycine substitutions in Gly‑X‑Y repeats → abnormal triple helix and matrix). (hasegawa2025osteogenesisimperfectapathogenesis pages 1-2, lin2024genotype–phenotyperelationshipand pages 2-4)
- **Collagen folding and post-translational modification** (e.g., CRTAP/P3H1/PPIB prolyl 3‑hydroxylation complex; ER chaperones such as SERPINH1/FKBP10). (panzaru2023classificationofosteogenesis pages 4-5, jovanovic2024updateonthe pages 2-4, zhou2024geneticanalysisphenotypic pages 9-9)
- **Collagen processing/trafficking and matrix cross-linking** (e.g., BMP1 processing pathways; chaperone/trafficking factors). (panzaru2023classificationofosteogenesis pages 4-5, jovanovic2024updateonthe pages 2-4)
- **Bone mineralization and bone quality defects** (e.g., SERPINF1/PEDF-related OI type VI). (panzaru2023classificationofosteogenesis pages 4-5, jovanovic2024updateonthe pages 8-9)
- **Osteoblast differentiation and signaling networks** (e.g., WNT1, SP7, CREB3L1, MBTPS2, MESD, KDELR2, CCDC134, TENT5A), which connect OI to LRP5/6 and MAPK/ERK pathways and to osteoblast secretory programs. (jovanovic2024updateonthe pages 1-2, jovanovic2024updateonthe pages 2-4)

Mechanism-based classification proposals group OI by these pathogenic classes rather than by phenotype alone, explicitly to support diagnosis and therapy development. (yu2023pathogenicmechanismsof pages 1-2)

### 2. Recent developments and latest research (prioritized 2023–2024)

#### 2.1 Shift toward dyadic nosology (gene + phenotype)
A major recent trend is adoption of a “dyadic” naming approach in skeletal dysplasia nosology, pairing a clinical/phenotypic label (often grounded in Sillence types) with a genomic co-descriptor. This is motivated by the rapidly expanding number of OI and OI-like bone fragility entities (>40 genes in some summaries) and by the fact that clinical types can be genetically heterogeneous. (sillence2024adyadicnosology pages 1-2, sillence2024adyadicnosology pages 4-5)

Similarly, a 2024 genetics update argues that gene-based classification should be primary, with clinical severity as a secondary designation, because phenotype-only categories can obscure distinct molecular etiologies within the same “type,” potentially affecting prognosis and treatment decisions. (jovanovic2024updateonthe pages 1-2, jovanovic2024updateonthe pages 2-4)

#### 2.2 IFITM5 type V mechanism: ERK/SOX9-dependent osteoprogenitor differentiation defect
A high-impact 2024 study in *Journal of Clinical Investigation* used conditional knock-in models to demonstrate that the recurrent **IFITM5 c.-14C>T** OI type V variant acts via a neomorphic mechanism in early skeletal progenitors, activating ERK/MAPK signaling and increasing SOX9 activity, disrupting chondrocyte maturation and endochondral ossification and biasing osteo-chondroprogenitor differentiation. Pharmacologic ERK pathway inhibition partially rescued mineralization phenotypes in model systems, and Sox9 deletion improved growth plate architecture and low bone mass. (marom2024theifitm5mutation pages 3-6, marom2024theifitm5mutation pages 10-11, marom2024theifitm5mutation pages 1-2)

Notably, the same study explicitly reports model limitations: the mouse models did **not** recapitulate key human type V features like hyperplastic callus and interosseous membrane calcification, highlighting translational gaps between model and patient phenotypes. (marom2024theifitm5mutation pages 10-11)

#### 2.3 Recessive OI “collagen PTM complex” validated in new functional human evidence
A 2024 *JCEM* study of **CRTAP-related OI type VII** included functional analyses of patient osteoblasts and bone samples, showing reduced CRTAP mRNA/protein, reduced osteoblast number and osteoid changes, and **reduced prolyl 3-hydroxylation** at a key residue in the α1 chain of type I collagen, implicating impaired collagen modification and bone formation. (zhou2024geneticanalysisphenotypic pages 9-9)

In addition, a 2023 report in *Genes* supports the importance of intronic and population-specific variants in **P3H1 (LEPRE1)**, predicting aberrant splicing leading to truncation of the primary ER-retained isoform and severe OI type VIII phenotypes (including popcorn calcifications). (kantaputra2023afounderintronic pages 2-5)

### 3. Current applications and real-world implementations

#### 3.1 Bisphosphonates: mainstream but heterogeneous response and limited consensus
**Bisphosphonates are widely used** in pediatric OI, but optimal protocol and endpoints remain unsettled.

- **Infant/severe early life practice (2023):** Intravenous bisphosphonates are described as established standard care in severe infant OI, with reported increases in lumbar spine BMD, analgesic effects, and potential reductions in fracture rates/preservation of vertebral heights—yet dosing frequency varies between centers and initial infusions require careful monitoring (hypocalcemia risk; potential acute cardiorespiratory deterioration). (arundel2023earlylifemanagement pages 2-4)

- **Bone quality monitoring (2024):** A 2024 pediatric study used trabecular bone score (TBS) and demonstrated that treatment effects can differ by disease severity: in mild OI, BMD Z-scores increased with treatment duration, whereas in moderate-to-severe OI, TBS Z-score improved while aBMD Z-score did not, suggesting bone “quality” and density metrics can diverge and treatment goals may need stratification by severity. (futagawa2024trabecularbonescores pages 1-2)

- **Practice variation/health system gaps (2024):** A multi-country European “patient journey” qualitative study highlighted lack of consensus on when to start bisphosphonates and which route to use, with limited adult “medical home” structures and reactive adult care. (westerheim2024osteogenesisimperfectaa pages 1-2)

#### 3.2 Orthopedic/spine management: scoliosis progression and surgical benefit
Scoliosis is a common OI complication with genotype- and non-genetic modifiers.

A 2023 longitudinal cohort (n=290) reported:
- **Scoliosis prevalence 70.7%** (Cobb >10°), with 20.3% severe (>50°). (chen2023scoliosisinosteogenesis pages 1-2)
- Mean progression **2.7°/year** (95% CI 2.4–3.0), and older age increased odds of advanced progression (OR 1.13 per year). (chen2023scoliosisinosteogenesis pages 1-2)
- Among severe cases, **42.8%** underwent surgery with median Cobb reduction about **33°** (IQR 23–40). (chen2023scoliosisinosteogenesis pages 1-2)

This study also found genetic effects: COL1A1/2 cases tended toward milder/no scoliosis, whereas IFITM5, WNT1, and other recessive genes were more evenly distributed across scoliosis severity. (chen2023scoliosisinosteogenesis pages 1-2)

### 4. Quantitative epidemiology and recent cohort statistics (2023–2024 prioritized)

#### 4.1 Prevalence and genetic distribution
Recent reviews cite OI prevalence around **~1/15,000–1/20,000**. (hasegawa2025osteogenesisimperfectapathogenesis pages 1-2, yu2023pathogenicmechanismsof pages 1-2)

In a large 2024 Chinese cohort with genetic diagnoses in 560 patients (83.5% positivity among 671 clinically diagnosed), **COL1A1 variants accounted for 55% and COL1A2 for 29%** of detected pathogenic mutations, confirming the dominance of type I collagen gene causes while leaving substantial room for non-collagen and recessive forms. (lin2024genotype–phenotyperelationshipand pages 2-4, lin2024genotype–phenotyperelationshipand pages 1-2)

#### 4.2 Fracture and vertebral phenotype burden
In the same 2024 cohort of 414 probands:
- Peripheral fracture prevalence **96.6%**, with femur the most commonly affected site (34.7%). (lin2024genotype–phenotyperelationshipand pages 1-2)
- Vertebral compression fractures (VCF) in **43.5%** of patients. (lin2024genotype–phenotyperelationshipand pages 1-2, lin2024genotype–phenotyperelationshipand pages 4-5)
- Scoliosis prevalence **24.9%** overall (children 18.3%, adults 50.0%). (lin2024genotype–phenotyperelationshipand pages 4-5)

This cohort also reported genotype–severity relationships: biallelic variants and glycine substitutions were associated with more severe phenotypes than collagen haploinsufficiency (mildest), and COL1A2/biallelic variants were associated with more deformity and poorer mobility compared with COL1A1. (lin2024genotype–phenotyperelationshipand pages 1-2)

### 5. Mechanistic subtype differentiation and “high-value missing” OI entries

The table below provides a concrete proposal for a curated union of OI disease entries (explicit members), spanning classic types and high-value missing gene-defined subtypes.

| Proposed disease entry label | Key gene(s) | Inheritance | Primary mechanism class | Differentiating clinical clues | Notes on grouping inclusion rationale and any caveats |
|---|---|---|---|---|---|
| Osteogenesis imperfecta type I, COL1A1-related | COL1A1 | AD | Collagen quantity | Mild/nondeforming OI, blue sclerae, childhood fractures, variable hearing loss, DI less frequent | Core curated member; classic quantitative type I collagen defect; useful anchor for grouping boundary because mechanism and phenotype are prototypic OI (jovanovic2024updateonthe pages 2-4, jovanovic2024updateonthe pages 1-2) |
| Osteogenesis imperfecta type II, COL1A1/COL1A2-related | COL1A1, COL1A2 | AD, rarely mosaic/germline mosaic | Collagen structure/dominant-negative | Perinatal lethal or near-lethal, severe undermineralization, multiple prenatal fractures, beaded ribs | Include as classic lethal OI end of spectrum; same collagen-structural disease axis as types III/IV, but severity should not be used to split out of OI grouping (hasegawa2025osteogenesisimperfectapathogenesis pages 1-2, yu2023pathogenicmechanismsof pages 1-2) |
| Osteogenesis imperfecta type III, COL1A1/COL1A2-related | COL1A1, COL1A2 | AD | Collagen structure/dominant-negative | Progressive deformity, very high fracture burden, short stature, scoliosis, DI may occur, wheelchair dependence common | Core curated member; classic progressively deforming OI; often glycine substitutions and more severe than haploinsufficiency (lin2024genotype–phenotyperelationshipand pages 2-4, lin2024genotype–phenotyperelationshipand pages 4-5) |
| Osteogenesis imperfecta type IV, COL1A1/COL1A2-related | COL1A1, COL1A2 | AD | Collagen structure/dominant-negative | Moderate variable OI, normal/gray sclerae, fractures, deformity, DI variably present | Core curated member; genetically heterogeneous even within Sillence type, but still prototypic OI phenotype and should remain in union (jovanovic2024updateonthe pages 2-4, sillence2024adyadicnosology pages 5-7) |
| Osteogenesis imperfecta type V, IFITM5-related | IFITM5 | AD | Osteoblast differentiation/signaling | Hyperplastic callus, interosseous membrane calcification, radial head dislocation, dense metaphyseal bands, usually no blue sclera/DI | Include as explicit non-collagen OI member; recurrent c.-14C>T neomorphic variant defines a distinctive mechanistic and clinical subtype, not merely a type IV mimic (jovanovic2024updateonthe pages 8-9, marom2024theifitm5mutation pages 1-2) |
| Osteogenesis imperfecta type VI, SERPINF1-related | SERPINF1 | AR | Mineralization defect | Progressive bone fragility, vertebral compression, mineralization defect/histologic fish-scale osteoid, often no blue sclera | High-value missing member; canonical recessive OI due to PEDF deficiency and abnormal mineralization; should be included despite non-collagen mechanism because phenotype is intrinsic OI/bone fragility syndrome (panzaru2023classificationofosteogenesis pages 4-5, jovanovic2024updateonthe pages 2-4) |
| Osteogenesis imperfecta type VII, CRTAP-related | CRTAP | AR | Collagen folding/PTM/processing | Severe osteoporosis, deformity, rhizomelia/short limbs, white sclerae, severe fractures; some popcorn epiphyses | Core/high-value member; defect in CRTAP-P3H1-PPIB prolyl-3-hydroxylation complex with impaired collagen modification and bone formation (zhou2024geneticanalysisphenotypic pages 9-9, yu2023pathogenicmechanismsof pages 1-2) |
| Osteogenesis imperfecta type VIII, P3H1-related | P3H1 (LEPRE1) | AR | Collagen folding/PTM/processing | Severe or lethal OI, white sclerae, profound growth deficiency, bowed limbs, popcorn epiphyses, osteopenia | High-value missing member; mechanistically adjacent to CRTAP/PPIB and strongly supports inclusion of collagen PTM complex disorders in grouping (kantaputra2023afounderintronic pages 2-5, yu2023pathogenicmechanismsof pages 1-2) |
| Osteogenesis imperfecta type IX, PPIB-related | PPIB | AR | Collagen folding/PTM/processing | Moderate-severe recessive OI, fractures, short stature, deformity, possible white sclerae | High-value missing member; same prolyl-3-hydroxylation/folding complex as CRTAP/P3H1; fits intrinsic OI grouping well (jovanovic2024updateonthe pages 2-4, yu2023pathogenicmechanismsof pages 1-2) |
| Osteogenesis imperfecta type X, SERPINH1-related | SERPINH1 | AR | Collagen folding/PTM/processing | Severe deforming OI, fractures, growth deficiency | Include; ER collagen chaperone defect causing delayed folding/secretion and classic OI bone fragility phenotype (panzaru2023classificationofosteogenesis pages 4-5, jovanovic2024updateonthe pages 2-4) |
| Osteogenesis imperfecta type XI, FKBP10-related | FKBP10 | AR | Collagen folding/PTM/processing | OI with deformity; may overlap Bruck syndrome with congenital contractures | Include, but curate carefully because FKBP10 spans both OI and Bruck presentations; include entries explicitly curated as OI or OI/Bruck, not all arthrogryposis-only phenotypes (panzaru2023classificationofosteogenesis pages 4-5, jovanovic2024updateonthe pages 2-4) |
| Osteogenesis imperfecta type XIII, BMP1-related | BMP1 | AR | Collagen folding/PTM/processing | Bone fragility with abnormal procollagen processing; may show high bone mass in some C-propeptide/processing contexts | Include; bona fide OI mechanism via procollagen C-propeptide processing; phenotype can be atypical, so disease labels should be gene-specific and curated (jovanovic2024updateonthe pages 2-4, yu2023pathogenicmechanismsof pages 1-2) |
| WNT1-related osteogenesis imperfecta | WNT1 | AR, AD in some familial osteoporosis/bone fragility contexts | Osteoblast differentiation/signaling | Early severe fractures, deformity, low BMD, scoliosis; in some families neurologic features reported | Include OI-designated WNT1 bone fragility disorders; caveat that WNT1 also overlaps familial osteoporosis, so boundary should prefer entities curated as OI or severe congenital bone fragility, not all WNT1 osteoporosis entries (lin2024genotype–phenotyperelationshipand pages 2-4, chen2023scoliosisinosteogenesis pages 1-2) |
| CREB3L1-related osteogenesis imperfecta | CREB3L1 | AR | Osteoblast differentiation/signaling | Severe prenatal/perinatal bone fragility, very low collagen matrix output, possible lethal presentation | Include as mechanistically strong OI entry because OASIS/CREB3L1 is central to osteoblast collagen secretion program; often severe and distinctive (jovanovic2024updateonthe pages 2-4) |
| SP7-related osteogenesis imperfecta | SP7 | AR | Osteoblast differentiation/signaling | Fractures with osteopenia/low BMD, deformity, delayed mineralization | Include; osteoblast transcription-factor defect causing intrinsic bone fragility within accepted OI genetic spectrum (jovanovic2024updateonthe pages 2-4) |
| TMEM38B-related osteogenesis imperfecta | TMEM38B | AR | Osteoblast differentiation/signaling | Variable recessive OI, fractures, vertebral compression, deformity; severity variable | Include; accepted recessive OI with osteoblast/ER calcium-homeostasis mechanism and intrinsic fragility phenotype (jovanovic2024updateonthe pages 2-4, bayanova2025geneticlandscapeand pages 2-3) |
| PLOD2-related Bruck syndrome / OI-like bone fragility | PLOD2 | AR | Collagen folding/PTM/processing | Bone fragility plus congenital contractures/arthrogryposis, kyphoscoliosis, Bruck phenotype | Borderline but recommended inclusion if grouping intends explicit OI-plus-core bone fragility syndromes; caveat: should be labeled as Bruck syndrome/OI-like rather than collapsed into classic OI, because contractures are a key differentiator (sillence2024adyadicnosology pages 4-5, sillence2024adyadicnosology pages 8-9) |
| MESD-related osteogenesis imperfecta | MESD | AR | Osteoblast differentiation/signaling | Severe bone fragility, low BMD, deformity; linked to LRP5/6 trafficking | High-value missing member; supports inclusion of WNT-pathway trafficking defects when phenotype is intrinsic OI rather than isolated osteoporosis (jovanovic2024updateonthe pages 1-2) |
| MBTPS2-related osteogenesis imperfecta | MBTPS2 | XR | Osteoblast differentiation/signaling | X-linked OI with fragility and possible extraskeletal features; overlaps osteoblast stress-response defects | Include; accepted OI mechanism via regulated intramembrane proteolysis/osteoblast differentiation axis, but note broader MBTPS2 phenotypic spectrum outside OI (jovanovic2024updateonthe pages 2-4) |
| KDELR2-related osteogenesis imperfecta | KDELR2 | AR | Collagen folding/PTM/processing | Recessive severe OI/bone fragility, deformity, low BMD | High-value missing member; accepted recent OI gene affecting collagen trafficking/retention; good example of why grouping should not be limited to classic numbered types (jovanovic2024updateonthe pages 1-2, jovanovic2024updateonthe pages 2-4) |
| CCDC134-related osteogenesis imperfecta | CCDC134 | AR | Osteoblast differentiation/signaling | Recessive OI/bone fragility, low bone mass, deformity; linked to MAPK/ERK pathway | High-value missing member; recently established and mechanistically relevant to signaling-based OI expansion beyond collagen biosynthesis genes (jovanovic2024updateonthe pages 1-2, jovanovic2024updateonthe pages 2-4) |
| TENT5A-related osteogenesis imperfecta | TENT5A | AR | Osteoblast differentiation/signaling | Childhood fractures, low bone mass, growth deficiency, dentin/tooth involvement reported in some cases | High-value missing member; recently validated OI gene affecting osteoblast secretory program/polyadenylation and collagen output, supporting inclusion in curated union (jovanovic2024updateonthe pages 1-2, jovanovic2024updateonthe pages 2-4) |


*Table: This table proposes an explicit curated union of osteogenesis imperfecta disease entries, organized by gene, mechanism, and distinguishing clinical features. It is useful for setting defensible grouping boundaries that include core and high-value missing OI entities while preserving important mechanistic caveats.*

Mechanistically, authoritative sources emphasize that Sillence types I–IV are now reserved for dominant collagen chain defects, while additional OI types include genes involved in collagen modification/folding, processing, mineralization, and osteoblast differentiation. (jovanovic2024updateonthe pages 2-4)

### 6. Defensible grouping boundary: what to include vs exclude

A curated dismech grouping should **not** be implemented as a copy of the MONDO OI subtree. Instead, it should be an explicit union of disease entries curated as intrinsic OI/brittle-bone disorders, plus carefully chosen boundary members. This is aligned with modern dyadic nosology that integrates phenotype and gene, and explicitly distinguishes intrinsic OI from other bone fragility syndromes and osteoporosis-like entities. (sillence2024adyadicnosology pages 1-2, sillence2024adyadicnosology pages 4-5)

The inclusion/exclusion logic and suggested HPO-based screening criteria are summarized here:

| Condition class | Include/Exclude | Rationale (mechanism/phenotype based) | Examples of disease entries | Notes for dismech YAML curation |
|---|---|---|---|---|
| Classic dominant OI due to quantitative type I collagen defect | Include | Core OI mechanism: reduced amount of normal type I collagen, typically COL1A1 haploinsufficiency; prototypic phenotype includes recurrent fractures, low BMD, blue sclerae, mild connective-tissue manifestations (jovanovic2024updateonthe pages 2-4, panzaru2023classificationofosteogenesis pages 1-2, jovanovic2024updateonthe pages 1-2) | Osteogenesis imperfecta type I; COL1A1-related OI type I | Make these explicit disease-entry members; prefer dyadic labels such as `osteogenesis imperfecta type I, COL1A1-related`; do not rely on all descendants of MONDO OI |
| Classic dominant OI due to structural/dominant-negative type I collagen defect | Include | Core OI mechanism: abnormal collagen helix/structure, usually COL1A1/COL1A2 glycine substitutions; spectrum spans perinatal lethal to progressively deforming to moderate OI (hasegawa2025osteogenesisimperfectapathogenesis pages 1-2, panzaru2023classificationofosteogenesis pages 2-4, yu2023pathogenicmechanismsof pages 1-2) | OI type II; OI type III; OI type IV; COL1A1-related and COL1A2-related forms | Include as separate explicit entries rather than a severity-only bucket; preserve type-level distinctions because type IV is genetically heterogeneous |
| IFITM5/BRIL-related non-collagen OI | Include | Accepted intrinsic OI subtype with distinctive osteoblast/signaling pathobiology rather than collagen quantity/structure defect; hallmark phenotype includes hyperplastic callus and interosseous membrane ossification (jovanovic2024updateonthe pages 8-9, marom2024theifitm5mutation pages 3-6, marom2024theifitm5mutation pages 1-2) | OI type V; IFITM5-related OI | Important boundary case proving OI grouping must not be collagen-gene-only; include by explicit curation |
| Recessive OI from collagen prolyl 3-hydroxylation / folding complex defects | Include | Canonical OI caused by CRTAP/P3H1(PLEPRE1)/PPIB complex dysfunction, impairing collagen post-translational modification, folding, and bone formation (panzaru2023classificationofosteogenesis pages 4-5, zhou2024geneticanalysisphenotypic pages 9-9, kantaputra2023afounderintronic pages 2-5) | OI type VII (CRTAP); OI type VIII (P3H1/LEPRE1); OI type IX (PPIB) | High-value missing core members for curated union; add even if absent from current KB |
| Recessive OI from ER collagen chaperone / processing defects | Include | Intrinsic OI caused by defects in collagen folding, chaperoning, secretion, cross-linking, or processing (panzaru2023classificationofosteogenesis pages 4-5, jovanovic2024updateonthe pages 2-4, yu2023pathogenicmechanismsof pages 1-2) | SERPINH1-related OI type X; FKBP10-related OI type XI; BMP1-related OI type XIII | Curate as explicit entries; for FKBP10 note overlap with Bruck syndrome and distinguish disease labels carefully |
| OI from mineralization defects | Include | Accepted OI subtype where intrinsic bone fragility arises from abnormal matrix mineralization rather than primary collagen chain defect (panzaru2023classificationofosteogenesis pages 4-5, jovanovic2024updateonthe pages 2-4) | SERPINF1-related OI type VI | Include as core member; supports mechanism-based rather than collagen-only grouping |
| OI from osteoblast differentiation / signaling defects | Include | Recent authoritative reviews place WNT1, CREB3L1, SP7, TMEM38B, MESD, MBTPS2, KDELR2, CCDC134, TENT5A within OI spectrum when phenotype is intrinsic brittle-bone disease with low bone mass/fractures/deformity (jovanovic2024updateonthe pages 2-4, jovanovic2024updateonthe pages 1-2) | WNT1-related OI; CREB3L1-related OI; SP7-related OI; TMEM38B-related OI; MESD-related OI; MBTPS2-related OI; KDELR2-related OI; CCDC134-related OI; TENT5A-related OI | Add as high-value missing members when KB has disease-level entries; prefer dyadic names; avoid collapsing them into “other OI” |
| OI/Bruck overlap disorders explicitly curated as OI-like bone fragility syndromes | Include with caution | Some disorders such as PLOD2- or FKBP10-related Bruck syndrome share intrinsic collagen cross-linking defects and brittle-bone pathobiology but add congenital contractures; useful as optional edge members if grouping scope allows OI-related bone fragility syndromes (panzaru2023classificationofosteogenesis pages 4-5, sillence2024adyadicnosology pages 4-5, sillence2024adyadicnosology pages 8-9) | Bruck syndrome, PLOD2-related; Bruck syndrome, FKBP10-related | If included, do so explicitly and label as boundary members; do not silently inherit through MONDO; consider separate sibling grouping if strict scope is “OI only” |
| Familial osteoporosis / isolated low-BMD disorders without syndromic OI phenotype | Exclude by default | Bone fragility alone is insufficient if disease lacks the broader OI connective-tissue / developmental bone phenotype or is curated primarily as osteoporosis rather than OI (sillence2024adyadicnosology pages 1-2, jovanovic2024updateonthe pages 1-2, yu2023pathogenicmechanismsof pages 1-2) | Osteoporosis, WNT1-related familial osteoporosis; LRP5-related primary osteoporosis | Exclude unless source ontology/disease label explicitly curates disorder as OI; note this is a major boundary needed to avoid a MONDO bone-fragility clone |
| Secondary osteoporosis / acquired fragility | Exclude | Not a monogenic intrinsic OI disorder; pathogenesis is acquired, multifactorial, or secondary to treatment/endocrine disease rather than inherited matrix/osteoblast defect (sillence2024adyadicnosology pages 1-2, yu2023pathogenicmechanismsof pages 1-2) | Postmenopausal osteoporosis; glucocorticoid-induced osteoporosis | Explicit exclusion list recommended in YAML comments |
| Skeletal dysplasias with fractures but not curated as OI | Exclude | Some skeletal dysplasias can mimic prenatal/perinatal OI radiographically but have distinct developmental mechanisms and established non-OI diagnoses (sillence2024adyadicnosology pages 1-2, yu2023pathogenicmechanismsof pages 1-2) | Atelosteogenesis; achondrogenesis; thanatophoric or other non-OI dysplasias | Add explicit exclusions to prevent over-broad union based on fracture/deformity phenotype alone |
| Hypophosphatasia and other metabolic bone diseases | Exclude | Fragility may occur, but mechanism is mineral metabolism defect distinct from accepted OI nosology and not typically curated as OI (sillence2024adyadicnosology pages 1-2, yu2023pathogenicmechanismsof pages 1-2) | Hypophosphatasia | Important phenocopy exclusion in diagnostic and ontology curation contexts |
| Ehlers-Danlos/OI overlap conditions not explicitly curated as OI | Exclude by default | Connective-tissue overlap and fractures/joint hypermobility may resemble OI, but unless authoritative disease curation names them as OI or OI-like intrinsic bone fragility syndromes they should not enter the union (sillence2024adyadicnosology pages 1-2, sillence2024adyadicnosology pages 5-7) | EDS/OI overlap syndromes; connective-tissue disorders with hypermobility and fractures | Include only if disease entry itself is curated as OI or OI-related brittle bone syndrome |
| HPO screening phenotype: HP:0002757 Pathologic fracture / recurrent fractures | Core | Central clinical screen for OI case finding across types (lin2024genotype–phenotyperelationshipand pages 2-4, lin2024genotype–phenotyperelationshipand pages 1-2) | Seen across classic and recessive OI | Use as core screening HPO; if recurrent-fracture-specific term is available in implementation, pair with this broader term |
| HPO screening phenotype: HP:0000939 Osteopenia / HP:0004349 Reduced bone mineral density | Core | Low bone mass/BMD is a shared but not exclusive feature across OI forms (lin2024genotype–phenotyperelationshipand pages 4-5, chen2023scoliosisinosteogenesis pages 1-2) | Common across dominant and recessive OI | Use one or both depending HPO support in pipeline; core but not sufficient alone |
| HPO screening phenotype: HP:0002996 Bone deformity | Core | Shared consequence of chronic fragility and abnormal matrix in moderate/severe OI (lin2024genotype–phenotyperelationshipand pages 2-4, lin2024genotype–phenotyperelationshipand pages 4-5) | Bowing deformities, long-bone deformity | Core criterion for moderate/severe forms |
| HPO screening phenotype: HP:0004322 Short stature | Supportive | Common but variable; strengthens syndromic OI classification, especially severe/recessive forms (zhou2025thespectraof pages 5-8, lin2024genotype–phenotyperelationshipand pages 4-5) | Types III/IV and many recessive forms | Supportive rather than mandatory |
| HPO screening phenotype: HP:0000592 Blue sclerae | Supportive | Classic clue for COL1A1/COL1A2 mild OI; often absent in type V and some recessive forms (jovanovic2024updateonthe pages 2-4, sillence2024adyadicnosology pages 8-9) | Type I and some types III/IV | Good supportive discriminator, not universal |
| HPO screening phenotype: HP:0000707 Dentinogenesis imperfecta | Supportive | Common extraskeletal OI feature, especially more severe classic types; generally absent in type V (zhou2025thespectraof pages 5-8, jovanovic2024updateonthe pages 8-9) | Types III/IV; some COL1A1/COL1A2 forms | Supportive; useful for subtype distinction |
| HPO screening phenotype: HP:0000365 Hearing impairment | Supportive | Recognized multisystem manifestation in OI, especially later in life (jovanovic2024updateonthe pages 2-4, zhou2025thespectraof pages 5-8) | Adult classic OI and others | Supportive, age-dependent |
| HPO screening phenotype: HP:0002650 Scoliosis / HP:0002808 Kyphosis | Supportive | Very common complication in moderate/severe OI and associated with genotype/severity (chen2023scoliosisinosteogenesis pages 1-2, lin2024genotype–phenotyperelationshipand pages 4-5) | Type III/IV, recessive forms, WNT1/IFITM5 | Supportive; may be used as severity modifier |
| HPO screening phenotype: HP:0012506 Vertebral compression fracture | Supportive | Common in OI cohorts and clinically important for disease burden and treatment monitoring (lin2024genotype–phenotyperelationshipand pages 2-4, lin2024genotype–phenotyperelationshipand pages 4-5) | Many pediatric and adult OI cases | Strong supportive criterion |
| HPO screening phenotype: HP:0000973 Hyperplastic callus | Subtype-specific | Characteristic clue for IFITM5-related OI type V (jovanovic2024updateonthe pages 8-9, marom2024theifitm5mutation pages 1-2) | OI type V | Mark subtype-specific, not general-screening core |
| HPO screening phenotype: interosseous membrane ossification / calcification | Subtype-specific | Highly characteristic for OI type V boundary definition (jovanovic2024updateonthe pages 8-9, marom2024theifitm5mutation pages 1-2) | Forearm interosseous membrane ossification in IFITM5-related OI | Use whichever exact HPO term is supported locally; subtype-specific |
| HPO screening phenotype: HP:0001382 Joint hypermobility | Supportive/boundary | May occur in OI connective-tissue phenotype but is nonspecific and can broaden overlap with EDS (sillence2024adyadicnosology pages 5-7) | Some mild classic OI; overlap cases | Supportive only; do not use as core because it weakens specificity |


*Table: This table defines a defensible curated union for Osteogenesis Imperfecta, showing which disease classes to include or exclude and how to operationalize the boundary in dismech YAML. It also lists practical HPO screening criteria, distinguishing core shared features from supportive and subtype-specific signs.*

### 7. MONDO mapping strategy, HPO phenotype criteria, and dismech module-conformance notes

#### 7.1 MONDO mapping
Available tools in this run did not provide direct MONDO identifier lookups; therefore, **this report does not enumerate MONDO IDs** to avoid guessing. The recommended mapping workflow is:
1) Start from the dyadic nosology/gene-based subtype set (e.g., “OI type V, IFITM5-related”; “OI type VII, CRTAP-related”). (sillence2024adyadicnosology pages 1-2, jovanovic2024updateonthe pages 2-4)
2) For each disease entry in your knowledge base, map to the closest MONDO concept **by exact label + synonyms** and confirm cross-references (OMIM/Orphanet) where possible (as emphasized by dyadic nosology’s OMIM tie‑ins). (sillence2024adyadicnosology pages 4-5, sillence2024adyadicnosology pages 8-9)
3) Ensure grouping is a **curated union**: explicitly list members (as in artifact-00), and separately list explicit exclusions (as in artifact-01).

#### 7.2 HPO phenotype criteria for OI grouping
A practical HPO screening framework is included in artifact-01, differentiating core features (fractures, low BMD/osteopenia, deformity) from supportive (blue sclera, DI, hearing loss, scoliosis, VCFs) and subtype-specific signs (hyperplastic callus; interosseous membrane ossification for type V). (chen2023scoliosisinosteogenesis pages 1-2, lin2024genotype–phenotyperelationshipand pages 4-5, jovanovic2024updateonthe pages 8-9)

#### 7.3 dismech module conformance / gaps
Key conformance recommendations:
- Implement as **explicit union of Disease entries**, not “all MONDO descendants.” (sillence2024adyadicnosology pages 1-2, jovanovic2024updateonthe pages 1-2)
- Use a **dyadic naming pattern** for member disease entries where possible (phenotype type + gene-related), consistent with 2023–2024 nosology direction. (sillence2024adyadicnosology pages 1-2, jovanovic2024updateonthe pages 2-4)
- Track **boundary members** (e.g., Bruck syndrome) with explicit labels to prevent “scope creep.” (sillence2024adyadicnosology pages 4-5, sillence2024adyadicnosology pages 8-9)

Identified gaps for YAML curation:
- Programmatic MONDO ID resolution and GeneReviews/PMID anchoring were not available in tool outputs for this run; these should be completed via ontology API lookup and PubMed validation during curation.

### 8. Expert opinions and analysis (authoritative sources)

- **Mechanism-driven classification is needed:** A 2023 Orphanet review argues phenotype-only classifications are poorly structured and proposes mechanism-based grouping (collagen synthesis/processing/PTM/folding/crosslinking vs mineralization vs osteoblast differentiation). (yu2023pathogenicmechanismsof pages 1-2)
- **Dyadic nosology is preferred for clinical usability:** A 2024 Calcified Tissue International review advocates pairing traditional clinical labels with genomic co-descriptors (dyadic naming) to capture the expanding genetic landscape while retaining recognizable phenotype groupings. (sillence2024adyadicnosology pages 1-2, sillence2024adyadicnosology pages 4-5)
- **Clinical-type labels can mislead therapy/prognosis:** The 2024 genetics update emphasizes that individuals sharing a Sillence phenotype may have distinct genotypes and potentially different biology and treatment response; thus genetic classification should be primary. (jovanovic2024updateonthe pages 1-2, jovanovic2024updateonthe pages 2-4)

### 9. Knowledge gaps, nomenclature pitfalls, and model-system limitations

#### 9.1 Knowledge and evidence gaps
- **Therapeutic endpoints:** Bisphosphonates reliably increase BMD in many settings but fracture-endpoint evidence remains limited in many summaries, and optimal protocol is not established; severity-stratified goals may be needed. (arundel2023earlylifemanagement pages 2-4, futagawa2024trabecularbonescores pages 1-2)
- **Care pathway gaps:** Qualitative evidence indicates adult care is often fragmented and there is lack of consensus guidelines on when/how to initiate bisphosphonates and other long-term management components. (westerheim2024osteogenesisimperfectaa pages 1-2)

#### 9.2 Nomenclature pitfalls
- **Sillence type ≠ gene:** Contemporary reviews emphasize that some clinical types (notably “type IV”) are genetically heterogeneous and that historical numerical expansions in OMIM/clinical practice can become an “amalgamation,” motivating dyadic naming. (jovanovic2024updateonthe pages 2-4, sillence2024adyadicnosology pages 5-7)
- **OI vs familial osteoporosis:** Dyadic nosology discussions caution that bone fragility syndromes include OI, OI-like, and familial osteoporosis entities; the grouping boundary must be curated rather than inferred from hierarchy. (sillence2024adyadicnosology pages 1-2, sillence2024adyadicnosology pages 4-5)

#### 9.3 Model limitations relevant to collagen biology and therapy translation
- **IFITM5 type V models:** The 2024 JCI work notes its models did not recapitulate key human type V signs (hyperplastic callus/interosseous membrane calcification), underscoring that pathway insights (ERK/SOX9) may not fully predict hallmark patient phenotypes. (marom2024theifitm5mutation pages 10-11)
- **Rare recessive forms:** CRTAP/P3H1/PPIB disorders involve ER-based PTM/folding and may engage ER stress pathways; human tissue access and small sample sizes limit histologic and mechanistic generalizability. (zhou2024geneticanalysisphenotypic pages 9-9)

### 10. References (URLs, publication dates; PMID notes)
This report includes URLs/DOIs and publication dates as returned by tool metadata. PMIDs were **not provided by tool outputs** for most articles retrieved in this session; therefore PMIDs are not listed to avoid fabrication. Key sources:
- Jovanovic & Marini, “Update on the Genetics of Osteogenesis Imperfecta.” Calcified Tissue International. Aug 2024. https://doi.org/10.1007/s00223-024-01266-5 (jovanovic2024updateonthe pages 2-4)
- Sillence, “A Dyadic Nosology for Osteogenesis Imperfecta and Bone Fragility Syndromes.” Calcified Tissue International. Jun 2024. https://doi.org/10.1007/s00223-024-01248-7 (sillence2024adyadicnosology pages 1-2)
- Yu et al., “Pathogenic mechanisms of osteogenesis imperfecta, evidence for classification.” Orphanet Journal of Rare Diseases. Aug 2023. https://doi.org/10.1186/s13023-023-02849-5 (yu2023pathogenicmechanismsof pages 1-2)
- Lin et al., “Genotype–phenotype relationship…” Journal of Endocrinological Investigation. Jun 2024. https://doi.org/10.1007/s40618-023-02123-2 (lin2024genotype–phenotyperelationshipand pages 2-4)
- Chen et al., “Scoliosis in osteogenesis imperfecta…” Orphanet Journal of Rare Diseases. Sep 2023. https://doi.org/10.1186/s13023-023-02906-z (chen2023scoliosisinosteogenesis pages 1-2)
- Marom et al., “IFITM5 mutation… ERK/SOX9…” Journal of Clinical Investigation. Jun 2024. https://doi.org/10.1172/jci170369 (marom2024theifitm5mutation pages 3-6)
- Arundel & Borg, “Early Life Management of Osteogenesis Imperfecta.” Current Osteoporosis Reports. Sep 2023. https://doi.org/10.1007/s11914-023-00823-5 (arundel2023earlylifemanagement pages 2-4)
- Futagawa et al., “Trabecular bone scores… respond differently to bisphosphonate treatment…” Frontiers in Pediatrics. Dec 2024. https://doi.org/10.3389/fped.2024.1500023 (futagawa2024trabecularbonescores pages 1-2)
- Westerheim et al., “OI: a study of the patient journey in 13 European countries.” Orphanet Journal of Rare Diseases. Sep 2024. https://doi.org/10.1186/s13023-024-03345-0 (westerheim2024osteogenesisimperfectaa pages 1-2)



References

1. (jovanovic2024updateonthe pages 2-4): Milena Jovanovic and Joan C. Marini. Update on the genetics of osteogenesis imperfecta. Calcified Tissue International, 115:891-914, Aug 2024. URL: https://doi.org/10.1007/s00223-024-01266-5, doi:10.1007/s00223-024-01266-5. This article has 72 citations and is from a peer-reviewed journal.

2. (yu2023pathogenicmechanismsof pages 1-2): Hongjie Yu, Changrong Li, Huixiao Wu, Weibo Xia, Yanzhou Wang, Jiajun Zhao, and Chao Xu. Pathogenic mechanisms of osteogenesis imperfecta, evidence for classification. Orphanet Journal of Rare Diseases, Aug 2023. URL: https://doi.org/10.1186/s13023-023-02849-5, doi:10.1186/s13023-023-02849-5. This article has 36 citations and is from a peer-reviewed journal.

3. (jovanovic2024updateonthe pages 1-2): Milena Jovanovic and Joan C. Marini. Update on the genetics of osteogenesis imperfecta. Calcified Tissue International, 115:891-914, Aug 2024. URL: https://doi.org/10.1007/s00223-024-01266-5, doi:10.1007/s00223-024-01266-5. This article has 72 citations and is from a peer-reviewed journal.

4. (sillence2024adyadicnosology pages 1-2): David Owen Sillence. A dyadic nosology for osteogenesis imperfecta and bone fragility syndromes 2024. Calcified Tissue International, 115:873-890, Jun 2024. URL: https://doi.org/10.1007/s00223-024-01248-7, doi:10.1007/s00223-024-01248-7. This article has 34 citations and is from a peer-reviewed journal.

5. (lin2024genotype–phenotyperelationshipand pages 2-4): X. Lin, J. Hu, B. Zhou, Q. Zhang, Y. Jiang, O. Wang, W. Xia, X. Xing, and M. Li. Genotype–phenotype relationship and comparison between eastern and western patients with osteogenesis imperfecta. Journal of Endocrinological Investigation, 47:67-77, Jun 2024. URL: https://doi.org/10.1007/s40618-023-02123-2, doi:10.1007/s40618-023-02123-2. This article has 18 citations and is from a peer-reviewed journal.

6. (lin2024genotype–phenotyperelationshipand pages 4-5): X. Lin, J. Hu, B. Zhou, Q. Zhang, Y. Jiang, O. Wang, W. Xia, X. Xing, and M. Li. Genotype–phenotype relationship and comparison between eastern and western patients with osteogenesis imperfecta. Journal of Endocrinological Investigation, 47:67-77, Jun 2024. URL: https://doi.org/10.1007/s40618-023-02123-2, doi:10.1007/s40618-023-02123-2. This article has 18 citations and is from a peer-reviewed journal.

7. (hasegawa2025osteogenesisimperfectapathogenesis pages 1-2): Kosei Hasegawa. Osteogenesis imperfecta: pathogenesis, classification, and treatment. Clinical Pediatric Endocrinology, 34:152-161, Jan 2025. URL: https://doi.org/10.1297/cpe.2025-0009, doi:10.1297/cpe.2025-0009. This article has 4 citations and is from a peer-reviewed journal.

8. (panzaru2023classificationofosteogenesis pages 4-5): Monica-Cristina Panzaru, Andreea Florea, Lavinia Caba, and Eusebiu Vlad Gorduza. Classification of osteogenesis imperfecta: importance for prophylaxis and genetic counseling. World Journal of Clinical Cases, 11:2604-2620, Apr 2023. URL: https://doi.org/10.12998/wjcc.v11.i12.2604, doi:10.12998/wjcc.v11.i12.2604. This article has 34 citations.

9. (zhou2024geneticanalysisphenotypic pages 9-9): Bingna Zhou, Peng Gao, Jing Hu, Xiaoyun Lin, Lei Sun, Qian Zhang, Yan Jiang, Ou Wang, Weibo Xia, Xiaoping Xing, and Mei Li. Genetic analysis, phenotypic spectrum and functional study of rare osteogenesis imperfecta caused by crtap variants. The Journal of Clinical Endocrinology and Metabolism, 109:1803-1813, Jan 2024. URL: https://doi.org/10.1210/clinem/dgae025, doi:10.1210/clinem/dgae025. This article has 6 citations.

10. (jovanovic2024updateonthe pages 8-9): Milena Jovanovic and Joan C. Marini. Update on the genetics of osteogenesis imperfecta. Calcified Tissue International, 115:891-914, Aug 2024. URL: https://doi.org/10.1007/s00223-024-01266-5, doi:10.1007/s00223-024-01266-5. This article has 72 citations and is from a peer-reviewed journal.

11. (sillence2024adyadicnosology pages 4-5): David Owen Sillence. A dyadic nosology for osteogenesis imperfecta and bone fragility syndromes 2024. Calcified Tissue International, 115:873-890, Jun 2024. URL: https://doi.org/10.1007/s00223-024-01248-7, doi:10.1007/s00223-024-01248-7. This article has 34 citations and is from a peer-reviewed journal.

12. (marom2024theifitm5mutation pages 3-6): Ronit Marom, I-Wen Song, Emily C. Busse, Megan E. Washington, Ava S. Berrier, Vittoria C. Rossi, Laura Ortinau, Youngjae Jeong, Ming-Ming Jiang, Brian C. Dawson, Mary Adeyeye, Carolina Leynes, Caressa D. Lietman, Bridget M. Stroup, Dominyka Batkovskyte, Mahim Jain, Yuqing Chen, Racel Cela, Alexis Castellon, Alyssa A. Tran, Isabel Lorenzo, D. Nicole Meyers, Shixia Huang, Alicia Turner, Vinitha Shenava, Maegen Wallace, Eric Orwoll, Dongsu Park, Catherine G. Ambrose, Sandesh C.S. Nagamani, Jason D. Heaney, and Brendan H. Lee. The ifitm5 mutation in osteogenesis imperfecta type v is associated with an erk/sox9-dependent osteoprogenitor differentiation defect. Journal of Clinical Investigation, Jun 2024. URL: https://doi.org/10.1172/jci170369, doi:10.1172/jci170369. This article has 12 citations and is from a highest quality peer-reviewed journal.

13. (marom2024theifitm5mutation pages 10-11): Ronit Marom, I-Wen Song, Emily C. Busse, Megan E. Washington, Ava S. Berrier, Vittoria C. Rossi, Laura Ortinau, Youngjae Jeong, Ming-Ming Jiang, Brian C. Dawson, Mary Adeyeye, Carolina Leynes, Caressa D. Lietman, Bridget M. Stroup, Dominyka Batkovskyte, Mahim Jain, Yuqing Chen, Racel Cela, Alexis Castellon, Alyssa A. Tran, Isabel Lorenzo, D. Nicole Meyers, Shixia Huang, Alicia Turner, Vinitha Shenava, Maegen Wallace, Eric Orwoll, Dongsu Park, Catherine G. Ambrose, Sandesh C.S. Nagamani, Jason D. Heaney, and Brendan H. Lee. The ifitm5 mutation in osteogenesis imperfecta type v is associated with an erk/sox9-dependent osteoprogenitor differentiation defect. Journal of Clinical Investigation, Jun 2024. URL: https://doi.org/10.1172/jci170369, doi:10.1172/jci170369. This article has 12 citations and is from a highest quality peer-reviewed journal.

14. (marom2024theifitm5mutation pages 1-2): Ronit Marom, I-Wen Song, Emily C. Busse, Megan E. Washington, Ava S. Berrier, Vittoria C. Rossi, Laura Ortinau, Youngjae Jeong, Ming-Ming Jiang, Brian C. Dawson, Mary Adeyeye, Carolina Leynes, Caressa D. Lietman, Bridget M. Stroup, Dominyka Batkovskyte, Mahim Jain, Yuqing Chen, Racel Cela, Alexis Castellon, Alyssa A. Tran, Isabel Lorenzo, D. Nicole Meyers, Shixia Huang, Alicia Turner, Vinitha Shenava, Maegen Wallace, Eric Orwoll, Dongsu Park, Catherine G. Ambrose, Sandesh C.S. Nagamani, Jason D. Heaney, and Brendan H. Lee. The ifitm5 mutation in osteogenesis imperfecta type v is associated with an erk/sox9-dependent osteoprogenitor differentiation defect. Journal of Clinical Investigation, Jun 2024. URL: https://doi.org/10.1172/jci170369, doi:10.1172/jci170369. This article has 12 citations and is from a highest quality peer-reviewed journal.

15. (kantaputra2023afounderintronic pages 2-5): Piranit Nik Kantaputra, Salita Angkurawaranon, Worrachet Intachai, Chumpol Ngamphiw, Bjorn Olsen, Sissades Tongsima, Timothy C. Cox, and James R. Ketudat Cairns. A founder intronic variant in p3h1 likely results in aberrant splicing and protein truncation in patients of karen descent with osteogenesis imperfecta type viii. Genes, 14:322, Jan 2023. URL: https://doi.org/10.3390/genes14020322, doi:10.3390/genes14020322. This article has 5 citations.

16. (arundel2023earlylifemanagement pages 2-4): Paul Arundel and Stephanie A. Borg. Early life management of osteogenesis imperfecta. Current Osteoporosis Reports, 21:779-786, Sep 2023. URL: https://doi.org/10.1007/s11914-023-00823-5, doi:10.1007/s11914-023-00823-5. This article has 17 citations and is from a peer-reviewed journal.

17. (futagawa2024trabecularbonescores pages 1-2): Natsuko Futagawa, Kosei Hasegawa, Hiroyuki Miyahara, Hiroyuki Tanaka, and Hirokazu Tsukahara. Trabecular bone scores in children with osteogenesis imperfecta respond differently to bisphosphonate treatment depending on disease severity. Frontiers in Pediatrics, Dec 2024. URL: https://doi.org/10.3389/fped.2024.1500023, doi:10.3389/fped.2024.1500023. This article has 4 citations.

18. (westerheim2024osteogenesisimperfectaa pages 1-2): Ingunn Westerheim, Valerie Cormier-Daire, Scott Gilbert, Sean O’Malley, and Richard Keen. Osteogenesis imperfecta: a study of the patient journey in 13 european countries. Orphanet Journal of Rare Diseases, Sep 2024. URL: https://doi.org/10.1186/s13023-024-03345-0, doi:10.1186/s13023-024-03345-0. This article has 8 citations and is from a peer-reviewed journal.

19. (chen2023scoliosisinosteogenesis pages 1-2): Peikai Chen, Yapeng Zhou, Zhijia Tan, Yunzhi Lin, Daniel Li-Liang Lin, Jingwei Wu, Zeluan Li, Hiu Tung Shek, Jianbin Wu, Yong Hu, Feng Zhu, Danny Chan, Kenneth Man-Chee Cheung, and Michael Kai-Tsun To. Scoliosis in osteogenesis imperfecta: identifying the genetic and non-genetic factors affecting severity and progression from longitudinal data of 290 patients. Orphanet Journal of Rare Diseases, Sep 2023. URL: https://doi.org/10.1186/s13023-023-02906-z, doi:10.1186/s13023-023-02906-z. This article has 10 citations and is from a peer-reviewed journal.

20. (lin2024genotype–phenotyperelationshipand pages 1-2): X. Lin, J. Hu, B. Zhou, Q. Zhang, Y. Jiang, O. Wang, W. Xia, X. Xing, and M. Li. Genotype–phenotype relationship and comparison between eastern and western patients with osteogenesis imperfecta. Journal of Endocrinological Investigation, 47:67-77, Jun 2024. URL: https://doi.org/10.1007/s40618-023-02123-2, doi:10.1007/s40618-023-02123-2. This article has 18 citations and is from a peer-reviewed journal.

21. (sillence2024adyadicnosology pages 5-7): David Owen Sillence. A dyadic nosology for osteogenesis imperfecta and bone fragility syndromes 2024. Calcified Tissue International, 115:873-890, Jun 2024. URL: https://doi.org/10.1007/s00223-024-01248-7, doi:10.1007/s00223-024-01248-7. This article has 34 citations and is from a peer-reviewed journal.

22. (bayanova2025geneticlandscapeand pages 2-3): Mirgul Bayanova, Aigerim Abilova, Marzhan Rakhimzhanova, Assiya Bazenova, Lyazzat Nazarova, Dias Malik, Naanlep Matthew Tanko, Nursulu Altaeva, and Aidos Bolatov. Genetic landscape and phenotypic spectrum of osteogenesis imperfecta in the kazakhstani pediatric population. Scientific Reports, Apr 2025. URL: https://doi.org/10.1038/s41598-025-95877-z, doi:10.1038/s41598-025-95877-z. This article has 2 citations and is from a peer-reviewed journal.

23. (sillence2024adyadicnosology pages 8-9): David Owen Sillence. A dyadic nosology for osteogenesis imperfecta and bone fragility syndromes 2024. Calcified Tissue International, 115:873-890, Jun 2024. URL: https://doi.org/10.1007/s00223-024-01248-7, doi:10.1007/s00223-024-01248-7. This article has 34 citations and is from a peer-reviewed journal.

24. (panzaru2023classificationofosteogenesis pages 1-2): Monica-Cristina Panzaru, Andreea Florea, Lavinia Caba, and Eusebiu Vlad Gorduza. Classification of osteogenesis imperfecta: importance for prophylaxis and genetic counseling. World Journal of Clinical Cases, 11:2604-2620, Apr 2023. URL: https://doi.org/10.12998/wjcc.v11.i12.2604, doi:10.12998/wjcc.v11.i12.2604. This article has 34 citations.

25. (panzaru2023classificationofosteogenesis pages 2-4): Monica-Cristina Panzaru, Andreea Florea, Lavinia Caba, and Eusebiu Vlad Gorduza. Classification of osteogenesis imperfecta: importance for prophylaxis and genetic counseling. World Journal of Clinical Cases, 11:2604-2620, Apr 2023. URL: https://doi.org/10.12998/wjcc.v11.i12.2604, doi:10.12998/wjcc.v11.i12.2604. This article has 34 citations.

26. (zhou2025thespectraof pages 5-8): Siji Zhou, Xiuzhi Ren, Yixuan Cao, Huan Mi, Mingchen Han, Lulu Li, Chendan Jiang, Yuqian Ye, Chaoqun Zheng, Binshan Zhao, Tao Yang, Nan Wu, Zhen Li, Lingqian Wu, and Xiuli Zhao. The spectra of pathogenic variants and phenotypes in a chinese cohort of 298 families with osteogenesis imperfecta. Genes, 16:416, Mar 2025. URL: https://doi.org/10.3390/genes16040416, doi:10.3390/genes16040416. This article has 4 citations.

## Artifacts

- [Edison artifact artifact-00](Osteogenesis_Imperfecta-deep-research-falcon_artifacts/artifact-00.md)
- [Edison artifact artifact-01](Osteogenesis_Imperfecta-deep-research-falcon_artifacts/artifact-01.md)
